BLAINTRAVENOUSPOWDER, FOR INJECTION SOLUTION, LYOPHILIZED POWDERPriority Review
Approved
Aug 2017
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
25
Data completeness
6/8 — Strong
Priority Review
BESPONSA (inotuzumab ozogamicin) by Pfizer is cd22-directed antibody interactions [moa]. First approved in 2017.
Drug data last refreshed 8h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BESPONSA (inotuzumab ozogamicin) is a CD22-directed immunoconjugate monoclonal antibody approved in 2017 for relapsed or refractory B-cell precursor acute lymphoblastic leukemia. It binds to CD22 on B-cells and delivers a cytotoxic payload to kill leukemic cells. The drug represents a targeted approach to hematologic malignancy treatment combining antibody specificity with chemotoxin potency.
$0.002BPart D
PeakProduct is in peak commercial phase with modest Part D penetration (19 claims in 2023), suggesting a specialized niche market with stable but limited growth opportunities.
Mechanism of Action
CD22-directed Antibody Interactions
Pharmacologic Class:
CD22-directed Immunoconjugate
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (25)
A Study to Learn About the Safety of BESPONSA Injection in Pediatric Patients With Acute Lymphocytic Leukemia.
Started Nov 2024
10 enrolled
Acute Lymphocytic Leukemia
Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma
Started Jun 2023
68 enrolled
B Acute Lymphoblastic LeukemiaB Lymphoblastic Lymphoma
A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL
Started May 2023
100 enrolled
ACUTE LYMPHOBLASTIC LEUKEMIA
A Study of Patients Who Received Inotuzumab Ozogamicin for B-cell ALL (Acute Lymphoblastic Leukemia) That Occurred Again After the Last Treatment
Started Mar 2023
32 enrolled
Adult Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia
A Study of Inotuzumab Ozogamicin in Chinese Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Started Feb 2023
44 enrolled
Acute Lymphoblastic Leukemia
Worked on BESPONSA at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.